PF-Atlas › Clinical Trials › NCT01052948

The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events

Retrospective study- · Not specified

Registry ID
NCT01052948
Phase
Not specified
Status
Completed
Drug / intervention
Retrospective study-
Sponsor
Pfizer
Start
2007-01
Enrollment
86939

About this trial

To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2. Diffuse Pleural/pulmonary thickening and pericardial and retroperitoneal fibrosis 3. Heart failure 4. Total, cardiac and respiratory mortality

View NCT01052948 on ClinicalTrials.gov →

Explore related

All Retrospective study- trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT01052948 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.